NR4A1 and breast cancer: BC is classified into hormone receptor (HR)-positive/HER2-negative, HER2-positive, and triple-negative tumor subtypes based on estrogen or progesterone receptor expression and HER2 gene amplification (Burstein et al. 2021; Waks and Winer 2019).